Other OTC - Delayed Quote USD

Awakn Life Sciences Corp. (AWKNF)

0.1350 -0.0024 (-1.72%)
At close: April 26 at 3:57 PM EDT
Key Events
Loading Chart for AWKNF
DELL
  • Previous Close 0.1374
  • Open 0.1380
  • Bid --
  • Ask --
  • Day's Range 0.1350 - 0.1380
  • 52 Week Range 0.0422 - 0.3600
  • Volume 11,370
  • Avg. Volume 14,075
  • Market Cap (intraday) 6.285M
  • Beta (5Y Monthly) 2.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.

awaknlifesciences.com

44

Full Time Employees

January 31

Fiscal Year Ends

Recent News: AWKNF

Performance Overview: AWKNF

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AWKNF
33.40%
S&P/TSX Composite index
4.82%

1-Year Return

AWKNF
24.03%
S&P/TSX Composite index
7.48%

3-Year Return

AWKNF
--
S&P/TSX Composite index
7.87%

5-Year Return

AWKNF
--
S&P/TSX Composite index
7.87%

Compare To: AWKNF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AWKNF

Valuation Measures

Annual
As of 4/27/2024
  • Market Cap

    6.28M

  • Enterprise Value

    5.88M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.15

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.77

  • Enterprise Value/EBITDA

    -0.74

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -150.88%

  • Return on Equity (ttm)

    -8,495.30%

  • Revenue (ttm)

    1.56M

  • Net Income Avi to Common (ttm)

    -7.32M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    554.66k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.2M

Research Analysis: AWKNF

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: AWKNF

People Also Watch